Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wang, Jia Xing ^a   Yi, Yong ^a   Li, Yi Wei ^a   Cai, Xiao Yan ^a   He, Hong Wei ^a   Ni, Xiao Chun ^a   Zhou, Jian ^a   Cheng, Yun Feng ^a   Jin, Jian Jun ^a   Fan, Jia ^a   Qiu, Shuang Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Prognosis; Sirtuin

Indexed keywords

SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; SIRT3 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROBABILITY; PROTEIN EXPRESSION; SCHOOL CHILD; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SIRTUIN 3; SURVIVAL RATE;

EID: 84899954437     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-297     Document Type: Article

References (43)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 10.1016/S0140-6736(11)61347-0, 22353262.
2. Yoon CY, Park MJ, Lee JS, Lee SC, Oh JJ, Park H, Chung CW, Abdullajanov MM, Jeong SJ, Hong SK, Byun SS, Lee ES, Lee SE. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 2011, 185:1102-1111. 10.1016/j.juro.2010.10.034, 21255805.
3. Kim TH, Jung JA, Kim GD, Jang AH, Cho JJ, Park YS, Park CS. The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice. Int Immunopharmacol 2010, 10:1310-1315. 10.1016/j.intimp.2010.08.004, 20728595.
4. Anh TD, Ahn MY, Kim SA, Yoon JH, Ahn SG. The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells. Oncol Rep 2012, 27:455-460.
5. Royce SG, Dang W, Yuan G, Tran J, El-Osta A, Karagiannis TC, Tang ML. Effects of the histone deacetylase inhibitor, trichostatin A, in a chronic allergic airways disease model in mice. Arch Immunol Ther Exp (Warsz) 2012, 60:295-306. 10.1007/s00005-012-0180-3, 22684086.
6. Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30:2986-2996. 10.1038/onc.2011.37, 3134877, 21358671.
7. Jeseta M, Petr J, Krejcova T, Chmelikova E, Jilek F. In vitro ageing of pig oocytes: effects of the histone deacetylase inhibitor trichostatin A. Zygote 2008, 16:145-152.
8. Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, Gottesman MM. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 2008, 6:1499-1506. 10.1158/1541-7786.MCR-07-2130, 2597364, 18723829.
9. Yu WP, Scott SA, Dong WF. Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells. Cell Prolif 2008, 41:86-97. 10.1111/j.1365-2184.2007.00499.x, 18211287.
10. Seo JS, Cho NY, Kim HR, Tsurumi T, Jang YS, Lee WK, Lee SK. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. Oncol Rep 2008, 19:93-98.
11. Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ. Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chin Med J (Engl) 2007, 120:2112-2118.
12. Sourlingas TG, Kypreou KP, Topakas GN, Karchilaki IN, Stavropoulos-Giokas C, Sekeri-Pataryas KE. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age. Ann N Y Acad Sci 2007, 1119:64-71. 10.1196/annals.1404.014, 18056955.
13. Schnur N, Seuter S, Katryniok C, Radmark O, Steinhilber D. The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim Biophys Acta 2007, 1771:1271-1282. 10.1016/j.bbalip.2007.08.003, 17894944.
14. Zhang QC, Jiang SJ, Zhang S, Ma XB. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev 2012, 13:3471-3476. 10.7314/APJCP.2012.13.7.3471, 22994780.
15. Fenic I, Hossain HM, Sonnack V, Tchatalbachev S, Thierer F, Trapp J, Failing K, Edler KS, Bergmann M, Jung M, Chakraborty T, Steger K. In vivo application of histone deacetylase inhibitor trichostatin-a impairs murine male meiosis. J Androl 2008, 29:172-185.
16. Campanero MR, Herrero A, Calvo V. The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. Oncogene 2008, 27:1263-1272. 10.1038/sj.onc.1210735, 17724474.
17. Schumacker PT. SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell 2011, 19:299-300. 10.1016/j.ccr.2011.03.001, 3087169, 21397853.
18. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP, Haigis MC. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011, 19:416-428. 10.1016/j.ccr.2011.02.014, 3065720, 21397863.
19. Zhang YY, Zhou LM. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun 2012, 423:26-31. 10.1016/j.bbrc.2012.05.053, 22609775.
20. Novgorodtseva TP, Abakumov AI, Sorokina LV. Multidimensional statistical methods and the diagnostic significance of erythrocyte fatty acids in cardiovascular diseases. Klin Lab Diagn 2001, 3:13-16.
21. Flekna G, Schneeweiss W, Smulders FJ, Wagner M, Hein I. Real-time PCR method with statistical analysis to compare the potential of DNA isolation methods to remove PCR inhibitors from samples for diagnostic PCR. Mol Cell Probes 2007, 21:282-287. 10.1016/j.mcp.2007.02.001, 17383153.
22. Cecconi D, Donadelli M, Rinalducci S, Zolla L, Scupoli MT, Scarpa A, Palmieri M, Righetti PG. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007, 7:1644-1653. 10.1002/pmic.200600811, 17443844.
23. Kovacs P, Csaba G. The effect of histone deacetylase inhibitor trichostatin A (TSA) on the incorporation of 32P (Pi) and 3H-palmitic acid into the phospholipids of Tetrahymena. Cell Biochem Funct 2008, 26:39-42. 10.1002/cbf.1394, 17191269.
24. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011, 54:497-505. 10.1016/j.jhep.2010.07.044, 21112656.
25. Tian F, Marini AM, Lipsky RH. Effects of histone deacetylase inhibitor Trichostatin A on epigenetic changes and transcriptional activation of Bdnf promoter 1 by rat hippocampal neurons. Ann N Y Acad Sci 2010, 1199:186-193. 10.1111/j.1749-6632.2009.05175.x, 20633124.
26. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, Yu J, Ng HK, Ling MT, Huang AL, Cai XF, Ko BC. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 2011, 71:4138-4149. 10.1158/0008-5472.CAN-10-4274, 21527554.
27. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011, 20:487-499. 10.1016/j.ccr.2011.09.004, 3199577, 22014574.
28. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F. V gamma 9 V delta 2 T cell response to colon carcinoma cells. J Immunol 2005, 175:5481-5488. 10.4049/jimmunol.175.8.5481, 16210656.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
30. Reilly CM, Thomas M, Gogal R, Olgun S, Santo A, Sodhi R, Samy ET, Peng SL, Gilkeson GS, Mishra N. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 2008, 31:123-130. 10.1016/j.jaut.2008.04.020, 18650065.
31. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-254. 10.1016/S0955-0674(03)00002-4, 12648682.
32. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes Cancer 2013, 4:164-171. 10.1177/1947601913486351, 3764471, 24020007.
33. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010, 12:662-667. 10.1016/j.cmet.2010.11.015, 21109198.
34. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010, 40:893-904. 10.1016/j.molcel.2010.12.013, 3266626, 21172655.
35. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006, 348:1245-1253. 10.1016/j.bbrc.2006.07.185, 16904634.
36. Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 2006, 16:563-568.
37. Olaharski AJ, Ji Z, Woo JY, Lim S, Hubbard AE, Zhang L, Smith MT. The histone deacetylase inhibitor trichostatin a has genotoxic effects in human lymphoblasts in vitro. Toxicol Sci 2006, 93:341-347. 10.1093/toxsci/kfl068, 16857700.
38. Bell EL, Guarente L. The SirT3 divining rod points to oxidative stress. Mol Cell 2011, 42:561-568. 10.1016/j.molcel.2011.05.008, 3526939, 21658599.
39. Tien Kuo M, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog 2006, 45:701-709. 10.1002/mc.20240, 16652372.
40. Chung JS, Park S, Park SH, Park ER, Cha PH, Kim BY, Chung YM, Woo SR, Han CJ, Kim SB, Suh KS, Jang JJ, Lee K, Choi DW, Lee S, Lee GY, Hahm KB, Shin JA, Kim BS, Noh KH, Kim TW, Lee KH, Yoo YD. Overexpression of romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cells. Gastroenterology 2012, 143:1084-1094. e1087, 10.1053/j.gastro.2012.06.038, 22749933.
41. Lu Y, Nie J, Liu X, Zheng Y, Guo SW. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod 2010, 25:1014-1025. 10.1093/humrep/dep472, 20118114.
42. Ninios YP, Sekeri-Pataryas KE, Sourlingas TG. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A. Leuk Res 2010, 34:786-792. 10.1016/j.leukres.2009.09.004, 19782399.
43. Ellis JK, Chan PH, Doktorova T, Athersuch TJ, Cavill R, Vanhaecke T, Rogiers V, Vinken M, Nicholson JK TMDE, Keun HC. Effect of the histone deacetylase inhibitor trichostatin a on the metabolome of cultured primary hepatocytes. J Proteome Res 2010, 9:413-419. 10.1021/pr9007656, 19894772.